Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target

Disc Medicine, Inc. (NASDAQ:IRON) is one of the 13 Small Cap Stocks Analysts Are Bullish On. In a report released on June 16, Thomas Smith from Leerink Partners maintained a Buy rating on Disc Medicine, Inc. (NASDAQ:IRON) with a price target of $85.00. The analyst based the rating on the company’s positive developments in its hematology-focused pipeline.

A scientist in a laboratory setting examining a sample of blood with a microscope.

Smith stated that Disc Medicine, Inc. (NASDAQ:IRON) is set to submit a New Drug Application for bitopertin, an oral GlyT1 inhibitor, that is anticipated to leverage an accelerated approval pathway. The HELIOS long-term extension study reported positive initial data supporting this progress, as it suggested improvements in live function, sustained reductions in PPIX, and a clean safety profile.

Disc Medicine, Inc. (NASDAQ:IRON) is also participating in ongoing trials, such as the Phase 2 RALLY-MF trial and the Phase 1b MF anemia trial, which have shown positive results with improved biomarker responses. The analyst considers this another positive factor supporting the buy rating.

Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes treatments for hematologic diseases.

While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.